Israel-Hezbollah Ceasefire Takes Effect Amid Rising Tensions Over U.S.-Iran Deal 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Trump Says Anthropic No Longer Seen as National Security Threat 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Iran Claims Strait of Hormuz Closure Amid Rising Middle East Tensions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Colombia Opens New Investigation Into Former President Álvaro Uribe Over Paramilitary Allegations 
The four types of dementia most people don’t know exist 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Gaza Death Toll Rises as Israeli Strikes Kill Nine Amid Ceasefire Stalemate 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Says He Will Visit Turkey and Return to China in 2026 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
